Effects of aging in stem cells

07-27-2007

There is little disagreement that the body’s maintenance and repair systems deteriorate with age, even as there is plenty of disagreement as to why. Stem cells combat the aging process by replenishing old or damaged cells—particularly in the skin, gut, and blood—with a fresh supply to maintain and repair tissue. Unfortunately, new evidence published in the open-access journal PLoS Biology suggests that this regenerative capacity also declines with age as stem cells acquire functional defects.

Stuart Chambers, Margaret Goodell, and their colleagues investigated the molecular mechanisms underlying aging of stem cells by looking at the gene expression profiles of aging hematopoietic stem cells (HSCs), the precursors of blood cells. They found that genes involved in the inflammatory and stress response became more active with age, while genes important for regulating gene expression and genomic integrity became less active. These results lend strong support to the notion that HSCs succumb to the wear and tear of aging, just like other cells, and shed light on the mechanisms of aging.

To study HSCs’ regenerative capacity over time, Chambers et al. isolated HSCs from young (aged 2 months) and old (aged 21 months) mice and then transplanted either young or old cells into mice whose bone marrow cells had been destroyed by radiation. The young and old HSCs gave rise to new marrow cells at roughly the same pace 4 weeks after transplantation. But at 8 and 16 weeks after transplantation, the old HSCs’ contributions had dropped considerably, suggesting that aging HSCs lose their repopulating capacity. Yet, because HSCs increased in number, overall blood production from HSCs remained stable.

The finding that genes involved in the inflammatory response are expressed more (called up-regulation) as HSCs age fits with evidence linking inflammation and aging in the kidney, brain, and arteries. It may also help explain why HSCs lose function. One of the up-regulated genes, P-selectin, encodes a cell surface adhesion molecule. Because transplanted HSCs depend on cell adhesion to colonize bone marrow properly, the researchers explain, inappropriate up-regulation of genes encoding P-selectin may interfere with this process.

The markedly reduced expression (or down-regulation) of genes involved in chromatin remodeling, an “epigenetic” regulator of gene expression, suggested that transcriptional activity might be dysregulated across the genome.

Though the dominant model attributes the physical effects of aging to an accretion of isolated genetic insults, these results link age-related decline to global mechanisms operating across the genome. In the researchers’ “epigenetic view of aging,” chromatin dysregulation provides a logical explanation for the numerous and diverse age-related changes observed at the molecular, cellular, and organismal levels. Over the normal course of aging, chromatin dysregulation leads to dysregulation of many genes, which in turn leads to a loss of normal cellular functions and a loss of growth regulation. These changes ultimately increase the risk of cancer, which, in many of its forms, increases dramatically with age. Future studies can investigate how epigenetic regulation, inflammation, and the stress response interact to better understand the molecular mechanisms of aging, and why so many of us face a high risk of cancer in our later years.

Citation: Chambers SM, Shaw CA, Gatza C, Fisk CJ, Donehower LA, et al. (2007) Aging hematopoietic stem cells decline in function and exhibit epigenetic dysregulation. PLoS Biol 5(8): e201. doi:10.1371/journal.pbio.0050201.

Image: Aging Hematopoietic Stem Cells
http://www.eurekalert.org/multimedia/pub/4577.php?from=98589

CONTACT:
Margaret Goodell
Baylor College of Medicine
Center for Cell and Gene Therapy
N1030
Houston, TX 77030
+1-713-798-1265
+1-713-798-1230 (fax)
goodell@bcm.edu

Source: PLoS BIOLOGY (www.plosbiology.org)



Related Keywords: Hematopoietic
Related Glossary Terms: Stem Cell
 
RECENT NEWS
 
Acute Lymphocytic Leukemia (ALL)
Risk of leukemia with multiple sclerosis drug higher than thought
Deciphera Pharmaceuticals Announces Initation of DCC-2036 Phase 1 Clinical Trial in Refractory CML and ALL
Oncogenic Kras Initiates Leukemia in Hematopoietic Stem Cells
Hana Biosciences Announces New Positive Interim Efficacy Results in Pivotal rALLy Clinical Trial of Marqibo in Acute Lymphoblastic Leukemia
New genes involved in acute lymphoblastic leukemia play fundamental role in prognosis of the disease
Acute Myeloid Leukemia (AML)
Cyclacel reports survival data from phase 2 sapacitabine study in elderly patients with acute myeloid leukemia
Risk of leukemia with multiple sclerosis drug higher than thought
A miR boost enables acute leukemia cells to mature
CSHL team develops mouse models of leukemia that predict response to chemotherapy
Oncogenic Kras Initiates Leukemia in Hematopoietic Stem Cells
Amyloidosis
High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis
STEM CELL TRANSPLANTATION PROCEDURE RESULTS IN LONG-TERM SURVIVAL FOR AMYLOIDOSIS PATIENTS
Neurochem receives approvable letter for eprodisate (KIACTA) for treatment of AA amyloidosis
Neurochem, Inc. (NRMX) Receives Approvable Letter for Eprodisate (KIACTA(TM)) for Treatment of AA Amyloidosis; FDA Asks for More Data
Aplastic Anemia
Blood Stem Cells Originate in the Placenta
Stem Cells from a Person's Own Umbilical Cord Effective Treatment For Life-Threatening Blood Disease, Study Data Show
Alexion's Soliris Granted Marketing Approval in Europe for Treatment of All Patients With PNH
Soliris(TM) Effective in PNH Patients With History of Aplastic Anemia and Myelodysplastic Syndromes
Decision Fails Patients with Transfusion-Dependent Anemia
Chronic Lymphocytic Leukemia (CLL)
ASCO Presentation Highlights Memgen's ISF35 Anti-Cancer Activity in Chronic Lymphocytic Leukemia
Genentech and Biogen Idec Submit Applications to the FDA for Rituxan for Most Common Type of Adult Leukemia
Oncogenic Kras Initiates Leukemia in Hematopoietic Stem Cells
Azerra MAA Accepted by EMEA for CLL
Roche's MabThera approved in Europe for CLL
Chronic Myeloid Leukemia (CML)
Deciphera Pharmaceuticals Announces Initation of DCC-2036 Phase 1 Clinical Trial in Refractory CML and ALL
Oncogenic Kras Initiates Leukemia in Hematopoietic Stem Cells
Scientists Gain Insight Into Blood Cancer's Progression
Some blood-system stem cells reproduce more slowly than expected
ARIAD Presents Preclinical Data on Its Kinase Inhibitor, AP24534, Demonstrating Inhibition of All Known Variants of the CML Target Protein Bcr-Abl
Hodgkin Lymphoma
Bone marrow stem cell co-transplantation prevents embryonic stem cell transplant-associated tumors
Seattle Genetics Receives FDA Fast Track Designation for SGN-35 for the Treatment of Hodgkin Lymphoma
Allos Therapeutics Submits New Drug Application for Pralatrexate for Patients with Relapsed or Refractory Peripheral T-cell Lymphoma
Study shows that maintenance rituximab is useful for advanced indolent lymphoma
Hodgkin lymphoma -- new characteristics discovered
Multiple Myeloma
New Australian Drug Holds Hope of Major Breakthrough in Treating Terminal Blood Cancers
Green Tea May Negate the Benefits of Velcade
Keryx Biopharmaceuticals (KERX) Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
Velcade® plus Perifosine Shows Promise in Relapsed or Refractory Multiple Myeloma
Mozobil™ Approved for Stem Cell Mobilization in NHL and MM Patients
Myelodysplastic Syndrome (MDS)
Oncogenic Kras Initiates Leukemia in Hematopoietic Stem Cells
Seattle Genetics Completes Enrollment in Lintuzumab Phase IIb Clinical Trial for Patients with Acute Myeloid Leukemia
New Risk Model for MDS Applies to All Stages of Disease
Seattle Genetics Announces Interim Safety Analysis Supports Continuation of Lintuzumab Phase IIb Clinical Trial
CHMP Awards Positive Opinion for Myelodysplastic Syndrome Drug
Non-Hodgkin Lymphoma (NHL)
Genentech and Biogen Idec Submit Applications to the FDA for Rituxan for Most Common Type of Adult Leukemia
Allos Therapeutics Submits New Drug Application for Pralatrexate for Patients with Relapsed or Refractory Peripheral T-cell Lymphoma
Spectrum Pharmaceuticals, Inc. Acquires 100% of ZEVALIN, an FDA-Approved, Proprietary, Biological Drug for Non-Hodgkin's Lymphoma
Study shows that maintenance rituximab is useful for advanced indolent lymphoma
Advances in the Treatment of Aggressive Non-Hodgkin’s Lymphoma
Testicular Cancer
Second gene linked to familial testicular cancer
Male Infertility Linked to Testicular Cancer
Single Dose of Carboplatin as Effective as Radiation Therapy for Testicular Cancer
Single Dose of Chemotherapy as Effective as Weeks of Radiation Therapy for Testicular Cancer
Drug avoids radiation for early testicular cancer